t
| Date | 15 Oct 2021 |
| Time | 09:00:02 |
| Category | Miscellaneous |
| ID | 1457P |
15 October 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Investor Presentation
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that Stuart Ashman, CEO, will provide a live presentation to investors via the Investor Meet Company platform on 26th Oct 2021 at 12:00pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics plc via:
https://www.investormeetcompany.com/skinbiotherapeutics-plc/register-investor
Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.
For more information please contact:
|
SkinBioTherapeutics plc Stuart J. Ashman, CEO Doug Quinn, CFO |
Tel: +44 (0) 161 468 2760 |
|
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson, Dale Bellis (Sales) |
Tel: +44 (0) 20 7397 8900 |
|
Instinctif Partners (financial press) Melanie Toyne-Sewell / Nathan Billis |
Tel: +44 (0) 20 7457 2020 |
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com.